Respiratory failure remains the most common complication in the perioperative period after lung transplantation. Consequently it is important to develop an approach to diagnosis and the treatment of respiratory failure in this population. This review highlights the advances made in the understanding and treatment of lung transplant patients in the early postoperative phase. Owing to its relative importance, advances in the understanding and treatment of ischaemia-reperfusion injury are highlighted.
Introduction
Lung transplantation is an accepted therapy for end-stage lung disease. Since 1985, the number of transplants reported to the International Society for Heart and Lung Transplantation has increased from 13 to 1703 in 2003 [1] . While the number of single lung transplants has remained relatively stable over the past 3 years, the number of double lung transplants has increased. This trend reflects changes in recipient characteristics and comorbidities, technical considerations, and a slight improvement in long-term outcome of patients who received a double lung transplant versus those who received a single lung.
Lung transplantation is associated with higher perioperative morbidity, mortality, and infectious complications relative to other solid organ transplants. Despite advances in surgical management and immunosuppression, 5 and 10-year survival following transplantation for most conditions has not changed [1] . This monotonous mortality rate must be placed in perspective and balanced against an increase in the number of high-risk transplant procedures. Since 1992, the number of recipients over the age of 50 has increased, with some centres transplanting patients over the age of 60. Patients with advanced and often unstable disease are also more commonly being considered for transplantation. Pressures to increase the donor pool, in the face of a scarce supply of organs, has led to the consideration of older donors and the use of more marginal lungs [2] [3] [4] . The use of marginal organs has been associated with a longer intensive care unit (ICU) course, a prolonged hospital stay, and lower pulmonary function at 1 year than recipients of optimal lungs [2] . The use of non-heart-beating donors presents the intensivist with both novel ethical dilemmas and unique physiological challenges [5, 6] . Ischaemic times of nonheart-beating donors are often increased, setting the stage for worse early graft function [6] . Living-related donation and lobar transplantation also possess unique physiological considerations. The transplanted lobes are more susceptible to hyperinflation during positive pressure ventilation, compounded by the application of negative pleural pressure during the application of chest drain suction. Indeed, haemodynamic collapse with the application of chest suction has been reported [7] . Lung volume reduction to compensate for lung size mismatching is also becoming more commonplace. The degree to which each of these factors contributes to the short and long-term outcomes remains an area of active investigation.
Anticipated complications following lung transplantation vary depending on the time since transplant (Table 1 ). In the immediate postoperative phase, technical concerns, haemorrhage, and mechanical complications are major concerns [8] [9] [10] [11] [12] . In the perioperative phase, ischaemiareperfusion injury remains the gravest concern. With time, the consequences of multisystem organ failure, acute rejection, and infectious complications predominate. In a recent review of 80 consecutive patients from a single centre, the most common causes of respiratory failure were reperfusion injury (55%) and perioperative cardiovascular/haemorrhagic events (36%) [13] . The mortality rate for patients who developed respiratory failure was 45%. Patients with preoperative pulmonary hypertension, right ventricular dysfunction, prolonged ischaemic time, and cardio-pulmonary bypass were more likely to develop respiratory failure. Beyond 3 months, infectious complications, malignancy, chronic rejection, and obliterative bronchiolitis remain leading causes of disability, hospitalization, and death. The outcome for patients readmitted to the ICU is poor [12] . In one cohort of 51 patients who were readmitted to the ICU (for a total of 73 admissions) the most common reasons for admissions were respiratory failure (51 of 73 admissions) and sepsis (five of 73 patients) [14] . A total of 40.7% of patients who required mechanical ventilation died in the ICU. Patients who died had experienced a greater reduction in forced expiratory volume in 1 s (FEV1) following transplantation and had higher APACHE III scores on admission to the intensive care unit.
Reperfusion injury
Despite advances in donor management, graft preservation and understanding of its pathophysiology, ischaemia-reperfusion injury remains the most common cause of respiratory failure. Ischaemia-reperfusion injury typically manifests in the first 72 h after transplantation. It is characterized by the development of airspace disease, progressive hypoxaemia, and increase in pulmonary pressures, reflecting both epithelial and endothelial injury. Although there is no uniform consensus regarding definition, most consider ischaemia-reperfusion injury to be severe when the PaO 2 /FiO 2 ratio is below 200, which is termed primary graft failure. Several risk factors for ischaemia-reperfusion injury have been evaluated. Our group recently identified that cardiopulmonary bypass use, body mass index greater than 25 kg/m 2 , immediate postoperative systolic pulmonary arterial pressure, trend in oxygenation index over 24 h, and APACHE II score to be important risk factors [11] . In a retrospective review of 752 patients from seven French transplantation centres over 12 years, graft ischaemic time was associated with the PaO 2 /FiO 2 ratio measured at 6 h [15] . The investigators identified a cold ischaemic time of 330 min as distinguishing between patients who had an uncomplicated course versus those who did not. Interestingly, an inverse relationship between ischaemic time and longterm survival was seen in patients undergoing single or double lung transplantation, but not in those who received a heart-lung transplant. A subsequent study from Australia identified the PaO 2 /FiO 2 ratio at 6 and 12 h to be significantly associated with the duration of intubation and length of ICU stay [16] . Importantly, 30-day mortality was found to be significantly associated with a lower PaO 2 /FiO 2 ratio at 6 h. It is unclear however, in either of these studies, whether manipulating PaO 2 / FiO 2 ratio would lead to an improvement in survival. That is, it is unclear whether patients die from respiratory failure or multisystem organ failure.
In addition to acute respiratory failure, ischaemia-reperfusion injury also has long-term consequences with an increased risk of infection, duration of hospitalization, and long-term graft function. In a retrospective cohort study of 255 consecutive lung transplant recipients, Christie et al. [9] reported a 30-day mortality of 63.3% compared with 8.8% in patients with and without reperfusion injury, respectively [9] . The median hospital [9] .
A variety of perturbations have been implicated in the pathogenesis of ischaemia-reperfusion injury [17] . These include factors relating to the donor, method of graft preservation and effects of implantation and reperfusion following a period of ischaemia. The transplanted lungs may initially be made susceptible to ischaemiareperfusion injury from cytokine-mediated damage in patients with raised intracranial pressure and compounded following cold preservation of the grafts. Alterations in the content of the electrolyte composition of the preservation solution, the addition of nitric oxide donors, prostanoids, and the depletion of leukocytes have been shown to reduce the incidence and severity of ischaemiareperfusion injury [17] [18] [19] [20] . Ensuring adequate inflation of the graft, preventing atelectasis and overdistension may also be effective in reducing ischaemia-reperfusion injury [17, 21] . Finally, reperfusion of the graft leads to a variety of insults resulting in epithelial and endothelial injury. Upregulation of adhesion molecules, cytokines, endothelin, cellular injury from lymphocytes and neutrophils, complement activation, increase in thromboxanes, apoptosis and reduction in endogenous nitric oxide have all been implicated [17, 22] .
These mechanistic observations have stimulated active research in preventing development of ischaemiareperfusion injury. In one of the few randomized trials in lung transplantation, Keshavjee and colleagues [23] recently reported that complement inhibition using a soluble complement receptor-1 inhibitor (TP-10) led to a reduction in duration of mechanical ventilation [23] . Interestingly, the greatest effect was seen in the subgroup of patients who received bypass during their transplant. Inhaled nitric oxide improves arterial oxygenation, ventilation perfusion matching, and has potentially relevant antiinflammatory properties. Early preclinical and uncontrolled clinical reports suggested that administration of nitric oxide either prior to or shortly after reperfusion injury could attenuate the severity of ischaemiareperfusion injury. A recent controlled clinical trial, however, failed to show the benefit of nitric oxide when inhaled 10 min after reperfusion [24] . Based on the pervasive biological rationale, it is likely that further work needs to be done to determine whether earlier application including administration of nitric oxide to donors would confer benefit in this group of patients.
Similar to other vascular beds, it has been suggested that ischaemia preconditioning may reduce subsequent ischaemia-reperfusion injury. Using this approach, Waldow and coworkers [25] demonstrated that preconditioning using a non-pulmonary vascular bed (hind-limb) attenuated the ischaemia-reperfusion mediated lung injury. Gene transfer has been achieved experimentally using vectors such as viruses to allow the endobronchial transfer of several proteins of interest. Recently, gene transfer of soluble type 1 interleukin-1 (IL-1) receptor, IL-10, and IkB suppressor gene has been shown to attenuate ischaemia-reperfusion injury in animal models [26] [27] [28] .
Care provided in the ICU may also affect the severity of ischaemia-reperfusion injury. Balyasnikova et al. [29] recently reported that propofol may be capable of attenuating the degree of lung dysfunction after transplantation. The administration of propofol in an isolated perfused rat lung model decreased ischaemia-reperfusion injury induced angiotensin-converting enzyme inhibitor release (a marker of oxidative lung injury). Fluid management may also influence the degree of lung dysfunction: in a retrospective study involving 118 transplant patients, after controlling for cardiac disease and vasopressor requirements, central venous pressure (CVP) was correlated positively with duration of mechanical ventilation, with a CVP greater than 7 mmHg also being associated with higher ICU and hospital mortality rates [30] . It is unclear, however, whether a strategy aimed at keeping CVP less than 7 mmHg would alter outcome or whether a high CVP was merely a marker of severity of illness. The balance between the maintenance of adequate filling pressures and attendant cardiac output is often in direct conflict with the desire to minimize lung water in these patients.
For patients with ischaemia-reperfusion injury and low PaO 2 /FiO 2 ratio, the adoption of a lung protective strategy would seem reasonable. Only one study, however, has evaluated the effect of lung volumes during mechanical ventilation in acute ischaemia-reperfusion injury [31] . In a rat lung transplant model, a reduction in tidal volume and use of sufficient positive end-expiratory pressure to keep the lung above the lower inflection point (as identified on its pressure-volume curve) was associated with an improvement in lung function following ischaemia-reperfusion. In patients who develop refractory hypoxaemia, the use of inhaled nitric oxide, surfactant, high-frequency ventilation, and extracorporeal membrane oxygenation (ECMO) may improve gas exchange [32, 33] . Earlier application of ECMO has been advocated for high-risk patients, such as those undergoing transplantation for pulmonary arterial hypertension. In a review of 17 patients, it was suggested that ECMO preserved initial organ function perhaps due to a reduction in the use of injurious ventilation strategies [34] . The small size and methodology of these reports, Early respiratory failure after lung transplantation Granton 21
however, prohibits the conclusion that ECMO actually leads to improved outcome in these patients.
Rejection
The distinction between acute reperfusion injury and acute rejection can be problematic. Patients manifest with alveolar infiltrates, hypoxaemia, and a systemic inflammatory response like syndrome. In a retrospective study in 41 patients who had a transbronchial biopsy, Burns and coworkers [35] reported that compared with a surgical biopsy, transbronchial biopsy tended to underestimate the presence and severity of rejection. Surgical biopsy increased the diagnosis of rejection in 33% of the cases and resulted in treatment changes in 15 of the 41 patients. They concluded that surgical biopsy was a valuable procedure in these patients. This recommendation is in contrast to earlier studies concluding that open lung biopsy early after transplant was of limited value in intubated patients [36] . In that report, a new diagnosis that changed therapy was made in only one of 11 early, and in eight of 27 late biopsies. At present, the utility of open lung biopsy has not been resolved; the risk of biopsy must be weighed against the potential yield of a biopsy in addition to the risk of simple empirical therapy for rejection after exclusion of infectious aetiologies. Given the consequences of the intensification of immunosuppression in the intubated, critically ill patient, open lung biopsy may be justifiable in selected cases.
Identification of patients at risk of acute rejection may aid in decision-making. Our centre recently reported that the presence of antibodies to human leukocyte antigens was associated with worse immediate outcome [37] . At present, patients who have panel reactive antibody levels greater than 25% receive plasmapharesis and intravenous immunoglobulin both prior to and following transplantation. The benefits of these interventions, however, remain to be proven.
Cardiac causes of prolonged mechanical ventilation
Atrial fibrillation or flutter commonly complicates the perioperative period. In a recent retrospective review of 200 adult patients from August 1998 to June 2002, postoperative atrial fibrillation within 14 days of transplant occurred in 39% of patients [38] . The mean onset of atrial fibrillation was 3.8 AE 3 days. Risk factors for arrhythmia included age greater than or equal to 50 years, idiopathic pulmonary fibrosis, coexisting coronary artery disease, enlarged left atrium, and use of vasopressors. Importantly, patients who developed atrial fibrillation had longer hospital stays (32.4 AE 60 days versus 17.5 AE 24.1 days, P ¼ 0.04), were more likely to undergo tracheotomy, and die in hospital. Finally, pulmonary embolism remains a likely underdiagnosed complication that may contribute to persistent hypoxaemia or haemodynamic instability in the early post-transplant period [39] .
Pneumonia
Pneumonia is a frequent postoperative complication, with the predominant organisms dependent on time since transplantation [40] . Infection of the donor lungs is frequently identified on cultures taken prior to transplantation. Staphylococcus aureus may be more prevalent in donor lungs given the high prevalence of this pathogen in brain-injured ventilated patients. Lung transplant patients may also be at risk for pneumonia because of colonization of the recipient's airway in the setting of transplantation for bronchiectasis and cystic fibrosis, or be at risk of aspiration in the presence of gastroesophageal reflux disease. The role of selective decontamination of the digestive tract (SDD) (typically consisting of a combination of enteral polymyxin B, tobramycin, and amphotericin B AE vancomycin in addition to a brief period of administration of parenteral cefotaxime) in lung transplantation has not been established. Although SDD has been evaluated in liver transplantation, its efficacy remains controversial [41, 42] . The application of this principle to lung transplant patients would seem rational, and concerns surrounding emergence of resistance using this technique remain relatively unfounded [43] .
Weaning
In patients who have an uncomplicated intraoperative course, early extubation may be feasible. In a study by Hansen and coworkers [44] , 53 of 73 patients were extubated in the operating room, only 11 of which required reintubation within the first 24 h. The requirement for reintubation increased hospital length of stay from 2 to 3 days. Risk factors for reintubation were not identified. In a separate study by Rocca et al. [45] , 12 of 43 patients were extubated early. Five of these required non-invasive pressure ventilation to avoid endotracheal intubation. The use of non-invasive ventilation to prevent reintubation in this population, however, must be tempered against a cautionary note raised by a recent trial demonstrating a worse outcome in patients treated with non-invasive ventilation after failed extubation [46] . Finally, the use of a weaning protocol incorporating spontaneous breathing trials may facilitate extubation [24] .
The failure to wean the patient following lung transplantation is often multifactorial:
(1) persistence of underlying lung injury; (2) perturbations in gas exchange; (3) uncontrolled surgical site pain; (4) delirium/encephalopathy; (5) inability to clear secretions; (6) muscular weakness; (7) phrenic nerve injury; (8) high ventilatory demands; (9) high patient workload; (10) patient-ventilator asynchrony; (11) anastamotic narrowing.
Phrenic nerve dysfunction has recently been described as a common complication following both heart-lung and lung transplantation [47] . A total of 43% (nine of 21 patients) following heart-lung transplant and 9.3% of lung transplant patients (nine of 97 patients) had demonstrable phrenic nerve dysfunction. This resulted in greater ventilator days, longer ICU length of stay and greater requirement for tracheotomy. Interestingly, an electro-myogram of the diaphragm demonstrated phrenic nerve derivation in five of the lung transplantation patients.
Conclusion
It is clear that advances in graft preservation and prevention of ischaemia-reperfusion injury are required to improve both immediate and long-term outcome after lung transplantation [48] . A reduction in ischaemia-reperfusion injury would stand to have a significant impact not only on early survival but also long-term outcome. It would be of interest to determine whether care of the transplant patient would be facilitated by the use of protocols to guide fluid administration, sedation, prevention of ventilatorassociated pneumonia, venous thromboembolism prophylaxis, weaning, and treatment of pneumonia.
